Share |

Content about Pharmacology

August 25, 2011

No one knows more about wasteful spending than the government, and healthcare is on top of most people’s list when it comes to wasteful spending. Since 2009 the focus has shifted towards bringing down the cost of healthcare spending.

August 24, 2011

One of the largest and most profitable biotechnology companies in the Mid-Atlantic is trying to increase its revenue by developing an oral form of treatment for pulmonary arterial hypertension (PAH).

Silver Spring-based United Therapeutics Corporation (NASDAQ: UTHR) released its FREEDOM-C(2) Phase 3 clinical trial results today but the company announced that the study did not meet its primary endpoint.

August 20, 2011

Rockville-based Catalyst Health Solutions (NASDAQ:CHSI) Chief Executive Officer, David Blair made the following,

Blair acquired 52,500 common stock shares at an average price of $6.62, for a total of 371,095 beneficially owned shares August 16, 2011.

Blair disposed of 52,500 common stock shares at an average price of $53.07 with 318,595 Beneficially Owned shares remaining August 16th, 2011.

August 16, 2011

Rockville-based Nabi Biopharmaceuticals (Nasdaq:NABI) has added to its cash stockpile by obtaining $5 Million in milestone payments from Fresenius USA Manufacturing, Inc.

June 27, 2011

The Chinese Biopharmaceutical Association held its annual event Sunday at the University System of Maryland, Shady Grove Campus in Rockville.

The 16th annual event for the association was represented by a large number of executives from China as well as the United States. The organization's members include scientists, attorneys, entrepreneurs and other professionals. More than four delegations in groups of ten or more attended the event, flying all the way from China.

June 16, 2011

Despite recession, several Maryland Biotechs turn a profit

Biotechnology firms have been reported to be hard hit by the recent recession; struggling to stay afloat amid a dearth of venture capital funding and and lack of new drugs selling on the market. The Biotech industry is often pigeonholed as frail, cash strapped and high risk; spending years on research to develop drugs but often ending with failure and bankruptcy.

But in Maryland it's a different story. Several biotech firms have achieved profitability for their full fiscal year and some of them for the first time in the midst of a troubled U.S. economy.

March 21, 2014

Washington, D.C.-based Vanda Pharmaceuticals Inc (NASDAQ:VNDA), has launched a couple of drugs and even recently put into place a television ad campaign. The company is now in need of extra space and will expand into an additional 8,600 square feet at its D.C. headquarters located at 2200 Pennsylvania Avenue.

Vanda will pay the landlord, Square 54 Office Owner LLC, and additional $381,000 for a 12 year and one month term lease beginning on September 1, 2014, although Vanda will get a nine month grace period.

March 13, 2014

In late 2012 Sucampo Pharmaceuticals (NASDAQ: SCMP) received approval from the Food and Drug Administration (FDA)  to expand upon its gastrointestinal drug -- AMITIZA -- to treat people with opioid-induced constipation (OIC) in the United States.

With increasing competition from other biotechnology companies, that approval is keeping the Bethesda-based drug developer ahead of them and profitable, with a net income posted in 3 out of the last 4 quarters of 2013, including the most recent fourth quarter.

March 13, 2014

Germantown, Maryland-based Intrexon Corporation (NYSE:XON) stock was recently upgraded by EVA Dimensions last week but that doesn’t explain yesterdays price surge of more than 10 percent for the company.

Intrexon was the third most price-trending stock on Google Finance yesterday, the stock price of the company increased more than 11.46 percent (+ $3.14) to close at $30.55 per share.

A few reasons that could have driven Intrexon’s stock price higher,

March 13, 2014

In late 2012 Sucampo Pharmaceuticals (NASDAQ: SCMP) received approval from the Food and Drug Administration (FDA)  to expand upon its gastrointestinal drug -- AMITIZA -- to treat people with opioid-induced constipation (OIC) in the United States.

With increasing competition from other biotechnology companies, that approval is keeping the Bethesda-based drug developer ahead of them and profitable, with a net income posted in 3 out of the last 4 quarters of 2013, including the most recent fourth quarter.

March 6, 2014

Silver Spring-based United Therapeutics (NASDAQ: UTHR) finished off 2013 with a strong showing, collecting revenues of over $1.1 billion for the first time in its corporate history as well posting a net profit for the full-year 2013 and upbeat 2014 outlook.

February 28, 2014

Silver Spring, Maryland-based United Therapeutics Corporation (NASDAQ:UTHR) crossed well over $1 billion in revenue for the first time in its corporate history and according to CEO Martine Rothblatt J.D., Ph.D., 2014 will be an even better year.

February 28, 2014

Shareholders of Gaithersburg, Maryland-based GlycoMimetics Inc (NASDAQ:GLYC) are already enjoying 42 percent gains after the company went public in January. The stock started off at $8 per share and has climbed to a high of $13.37, achieved only yesterday.

There’s some speculation as to why the stock price jumped 21 percent on February 25th, rumors range from short interest to major news on the way.

November 2, 2011

The biotech company narrows loss but revenues plummet

Nabi Biopharmaceuticals (Nasdaq:NABI) is recovering from its failed Phase III nicotine addiction drug trial back in July. The biotechnology company based in Rockville reported improved earnings for the third quarter ended September 26, 2011. It narrowed its net loss to $2.9 million or $-0.07 cents per share from $5.1 million or $-0.12 cents per share in third quarter of 2010 and $4.6 million in the second quarter ended June 26, 2011.

August 16, 2011

PharmAthene, Inc. (AMEX: PIP), an Annapolis based biodefense company, announced that they have been awarded $5.7 million by the Department of Defense (DoD) to continue research of its nerve agent medical countermeasure program.

The contract will allow PharmAthene to evaluate mammalian cell-based manufacturing system for rBChE for a period of 18 months. The company indicated that if the research is successful, it could increase production, flexibility, and be cost-effective.

August 4, 2011

Vanda Pharmaceuticals Inc., (NASDAQ: VNDA) which recently announced it would be moving its headquarters to 2200 Pennsylvania Avenue, N.W. in Washington, D.C., released disappointing financial results for the second quarter ended June 30, 2011.

Revenues plunged 28% to $14.9 Million in the six months ended June 30, 2011 from $20.7 Million at the end of June 30, 2010, a $5.78 Million difference.

A net loss of $1.2 Million was reported by the Rockville based company for the first half of the year.

July 19, 2011

The agreement could mean another merger and acquisition for the region

Another area based biotechnology company has partnered with a company on the other side of the country, a much larger company, far, far away from here.

This time it's Rockville based Micromet, Inc.

Micromet, Inc labels itself as a biopharmaceutical company focused on finding treatments for cancer through commercialization of innovative antibody based therapies. The company traces its root back to 1993 in Munich, Germany where a small group of scientists set upon treating cancer via T cell based therapies.

July 11, 2011

Press Release

"Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Probiomed S.A. de C.V. for Commercialization of Fanapt(TM) in Mexico